Cambridge Enterprise, University of Cambridge
Cambridge Enterprise exists to help University of Cambridge inventors, innovators and entrepreneurs make their ideas and concepts more commercially successful for the benefit of society, the UK economy, the inventors and the University.
|Address:||Hauser Forum, 3 Charles Babbage Road, Cambridge|
|Membership type:||Cambridge University Department|
Cambridge Enterprise Limited is responsible for the commercialisation of University of Cambridge intellectual property and is a wholly owned subsidiary of the University. Activities include management and licensing of intellectual property and patents, proof of concept funding and support for University staff and research groups wishing to provide expert advice or facilities to public and private sector organisations. Cambridge Enterprise provides access to angel and early stage capital through the Cambridge Enterprise Seed Funds and Cambridge Enterprise Venture Partners, and offers business planning, mentoring and other related programmes.
The University leads the world in transformative research and Cambridge Enterprise is well placed to support the academics to find the best commercialisation route for their innovations either through licensing, company creation or consultancy. Income over the past three years exceeded £27 million, of which over £22 million was distributed to University academics and departments, with the remainder reinvested in patent assets, seed fund pools and support for knowledge and technology transfer services to the University.
The website contains information on technologies available for licensing and details of companies formed with technology arising from the University of Cambridge. Cambridge Enterprise is also responsible for the commercial licensing of research reagents owned by the University.
Specialist geospatial database technology GeoSpock has secured £3.5m in Series A funding.
18 November 2015Read in full
Cambridge Enterprise, the commercialisation arm of the University of Cambridge, has launched a new film about its work.
9 November 2015Read in full
Cytora, a pioneer in event detection, whose risk analytics technology is deployed in some of the largest companies and governments in the world, has raised its second round of investment.
2 October 2015Read in full
An artificial pancreas given to children and adults with type 1 diabetes going about their daily lives has been proven to work for 12 weeks – meaning the technology, developed at the University of Cambridge, can now offer a whole school term of extra freedom for children with the condition.
22 September 2015Read in full
ERBA Diagnostics Mannheim GmbH, a global in vitro diagnostics company, today announced it has completed the acquisition of Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial markets. Financial terms were not disclosed.
16 September 2015Read in full
Collagen Solutions plc, the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, has acquired all of the assets and an exclusive worldwide licence for the associated intellectual property to ChondroMimetic from Orthomimetics Limited (OL) and Cambridge Enterprise (CE), the commercialisation arm of the University of Cambridge.
15 September 2015Read in full
Jukedeck, a University start-up and Cambridge Enterprise portfolio company, has been named one of WIRED’s ‘100 Hottest European Startups’ in 2015.
26 August 2015Read in full
Cambridge Enterprise and the Entrepreneurial Postdocs of Cambridge (EPOC) have launched a new business plan competition aimed at helping University of Cambridge postdocs successfully commercialise their ideas.
13 August 2015Read in full
The first ever event for investors to learn about prospective spin-out companies from both the Universities of Oxford and Cambridge was held at the London Stock Exchange last week.
20 May 2015Read in full
PhoreMost Ltd, a biopharmaceutical company and University of Cambridge spin-out founded to identify new druggable targets for cancer and other unmet diseases, announced that it has raised £2.5 million in seed funding from Cambridge-based investors: Jonathan Milner, Amadeus Capital, Sunil Shah and Prashant Shah (O2H Ventures), Cambridge Enterprise, and Dr Chris Torrance, PhoreMost’s CEO.
7 April 2015Read in full
Technology Manager (Life Science)
Sitting at the heart of Europe’s most successful technology cluster, Cambridge Enterprise is the commercialisation arm of the Un...
Salary: £0 - £0